Post-Paclitaxel: Will Boston Scientific Cut Guidant Royalty Deal?
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's reluctance to grant Medtronic a license in 2001 in its dispute over rapid-exchange delivery technology may set a precedent for the next stage of the Boston Scientific/Guidant fight over drug-eluting stents
You may also be interested in...
Centerpulse Rebounds 80% In Second Quarter As MDDI Index Drops 17%
Centerpulse stock surged 80.9% in the second quarter as final approval of a hip and knee class-action settlement dissipated the threat of bankruptcy, and the firm decided to divest its non-core businesses to focus on orthopedics. The issue closed at $16.55, up $7.40 for the three months
Centerpulse Rebounds 80% In Second Quarter As MDDI Index Drops 17%
Centerpulse stock surged 80.9% in the second quarter as final approval of a hip and knee class-action settlement dissipated the threat of bankruptcy, and the firm decided to divest its non-core businesses to focus on orthopedics. The issue closed at $16.55, up $7.40 for the three months
Cook Will Appeal Ruling Against Guidant Paclitaxel Stent Distribution
Guidant has vowed to "define an organizational construct" that "allows for the commercialization of paclitaxel-eluting stents," following a June 13 court ruling against its Cook distribution agreement for access to the drug